Correlation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis)

This study aims to measure a blood protein called fibroblast activation protein (FAP), which is linked to tissue scarring and inflammation. A small blood sample will be taken from participants (RA , SSc patients and healthy people ), and the FAP level will be measured and compared with routine clinical examinations, imaging studies, and lung function tests.

The purpose of this study is to improve understanding of disease activity and lung involvement in these conditions and to explore whether FAP could be useful as a blood marker for future patients. Participation in this study will not change the participant's usual medical care.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Rheumatoid Arthritis (RA) Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Fibrosis Immune System Diseases Joint Diseases Lung Diseases Lung Diseases, Interstitial Musculoskeletal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Fibrosis Respiratory Tract Diseases Rheumatic Diseases Scleroderma, Systemic Skin Diseases Skin and Connective Tissue Diseases Systemic Sclerosis (SSc)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University Hospital

Sohag, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥18 years. Confirmed diagnosis of RA (ACR/EULAR) or SSc (ACR/EULAR).
Ability and willingness to provide informed consent. Cooperative patient able to answer questions.

Exclusion criteria

Patients under 18 years' old
Active cancer or history of cancer within 5 years.
Other major fibrotic systemic disease that could confound circulating FAP levels.
Acute infection at time of sampling.
Pregnancy or breastfeeding.
Other autoimmune diseases

Treatment and study plan

Primary outcomes

Serum fibroblast activation protein (FAP) concentration measured by ELISA in patients with rheumatoid arthritis and systemic sclerosis

Time frame: At baseline (Day 1)

Secondary outcomes

disease activity

Time frame: baseline

Correlation between serum FAP concentration and disease activity score in rheumatoid arthritis and systemic sclerosis
pulmonary involvement

Time frame: baseline

Correlation between serum FAP concentration and pulmonary involvement in patients with rheumatoid arthritis and systemic sclerosis

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Circulating Fibroblast Activation Protein (FAP) As A Marker for Fibroblast-Driven Pathology in Rheumatoid Arthritis and Systemic Sclerosis : Implication for Joint, Skin and Lung Fibrosis

Acronym: FAP

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Feb 6, 2026
Registry last updated: Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting